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ABSTRACT 
 
Obesity and its associated disorders are a growing epidemic across the world.  Many genetic, physiological, and 
behavioral factors play a role in the etiology of obesity.  Diet and exercise are known to play a valuable role in 
the treatment and prevention of obesity and associated disorders such as hypertension, heart disease, and 
diabetes.  Therefore, the purpose of this review is to examine the prevalence, etiology, consequences, and 
treatment of obesity.  Journal of the International Society of Sports Nutrition.  2(2):4-31, 2005 
 
Key Words:  weight loss, diet, exercise, physical activity, leptin, cortisol, metabolic syndrome 
 
 
INTRODUCTION 
 
Approximately 1.2 billion people in the world are 
overweight and at least 300 million of them are 
obese.  According to the World Health Organization, 
obesity is one of the 10 most preventable health risks.  
Yet, at least 300,000 deaths every year in the United 
States alone can be linked to obesity.  Obesity is 
associated with disorders such as hypertension, 
diabetes, hypercholesterolemia, and liver disease.  
Obesity has been thought to simply be related to an 
imbalance between energy intake and expenditure.  
However, more recent research has suggested that 
genetic, physiological, and behavioral factors also 
play a significant role in the etiology of obesity.  
Thus, the management of obesity through exercise, 
nutrition, supplementation, and medical intervention 
are at the forefront of research.  The purpose of this 
review is to examine the current literature as it 
pertains to the prevalence, theories, medical 
consequences, management, and future research 
directions in the study of obesity.  Further, this 
review will provide practical recommendations in 
dealing with athletes and/or clients who are 
overweight. 
 
PREVALENCE AND SOCIETAL IMPACT OF 
OBESITY 
 
Obesity Prevalence in the United States 
 
The height/weight index considered to be the most 
popular of all indices1  is the body mass index (BMI).  
BMI is calculated by dividing a person’s weight in 
kilograms (kg) by the person’s height in meters 
squared (m2).    The World Health Organization 
(WHO) classifies normal weight as having a BMI 
(BMI) of 18.5 to 24.9 kg/m2, overweight 25 to 29 
kg/m2, moderately obese as greater than or equal to 
30 kg/m2, and morbidly obese as greater than or equal 
to 40 kg/m2 2, 3 .  The National Health Examination 
Survey (NHES) and the National Health and 
Nutrition Examination Surveys (NHANES) are cross-
sectional health examination surveys that are 
representative of the American population.  These 
surveys were conducted at the time points of: 1960-
1962 (NHES), 1971-1975 (NHANES I), 1976-1980 
(NHANES II), 1988-1994 (NHANES III), and 1999-
2000 (NHANES 1999-2000).  In adults ages 20-74, 
these surveys reported an alarming increase in the 
percent of respondents who were obese (i.e., 14.6, 
14.3, 14.5, 22.5, and 30.4, respectively)4 .  Perhaps of 
greater concern is that the prevalence of morbidly 
obese Americans is estimated to have increased 
three-fold from 1990 to 2000 (See Figure 1)5 .  
Overweight classification is increasing in children 
and adolescents as well.  From the NHANES I survey 
to the NHANES 1999-2000 surveys, prevalence of 
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obesity has increased  5.4% in 2-5 year old, 11.3% in 
6-11 year olds, and 9.4% in 12-19 year olds6 .  The 
data from the NHANES III to the most recent 
NHANES 1999-2000 has shown that the overweight 
prevalence in all age groups has increased 
significantly 6 .  These findings indicate that obesity 
has become a major health concern in the United 
States.  
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Figure 1:  Prevalence of obesity in the United States as indicated 
by the NHES and NHANES studies.  Note the progression of 
moderately and higher obese individuals and the diminishing of 
underweight and overweight individuals. 
 
Obesity Prevalence Worldwide 
 
The prevalence values for obesity in Europe as well 
as other countries with established market economies 
is estimated to average 15-20% of the population .  In 
1995, obesity in Europe was estimated to be 10-20% 
for men and 15-25% for women 7 .  More recently, 
European obesity has been estimated as high as 22% 
in children, and as high as 26% in men and 31% in 
women.  Cockram and colleagues8  reported that 
obesity and its related diseases such as type 2 
diabetes have also been increasing in the Asia-Pacific 
region of the world.  Obesity, especially central 
obesity, seems to be a primary reason for this 
increased rate of type 2 diabetes.  Interestingly, the 
BMI values currently used appear underestimates risk 
in Asians.  This might be due in part to many Asian 
races being more likely to develop abdominal 
obesity9 .  Therefore, the health-related consequences 
for Asia-Pacific individuals appear to be more intense 
at an absolute BMI value when compared to their 
European descendant counterparts.  A suggested 
method that is possibly a more accurate assessment is 
a waist-to-height ratio 10 .  This method was used by 
Hsieh and colleagues10  to determine the metabolic 
risk of Japanese men and women.  They discovered 
that nearly all of the “overweight” subjects had high 
metabolic risk value, and that 45.5% of men and 
28.3% of women of “normal weight” status also had 
high metabolic risk values when using the waist-to-
height ratio method.  Collectively, these findings 
indicate that obesity is not only a problem in the 
United States but is also a major health concern in 
Europe and other regions of the world.     
 
Societal Impact of Obesity 
 
The associated effect of obesity on type 2 diabetes, 
hypertension, coronary heart disease (CHD), 
gallbladder disease, osteoarthritis, and certain cancers 
gives rise to the increasing economic costs of obesity 
11 .  In 1999, the cost of obesity-related health care 
expenditures in the United States was estimated to be 
approximately 24 billion dollars 11 .  Physician office 
visits due to obesity increased by 88% from 1988 to 
1994 12 .  Moderately obese and severely obese 
individuals were estimated to have 14% and 25% 
more visits to their physicians, respectively, than 
normal weight individuals 13 .  Visits to primary 
physicians have been found to be 38% higher for 
obese individuals than normal weight persons14 .  Up 
to 2003, the total annual medical expenditure cost for 
the United States has been estimated to be 5-7% of 
total health care costs or about 75 billion dollars a 
year15 .   
  
The United States is not alone in its economic 
financial burden caused by obesity.  Europeans have 
also experienced an increased prevalence of obesity 
and have an estimated health care cost of 1-5% of 
total health care expenditures . In Europe, obesity-
related health care costs are among the most costly 
health care determinants.  In 1997, Canada was 
estimated to have a direct cost of obesity in excess of 
$1.8 billion16 .  Nearly one-third of Canadian adults 
have been estimated to be at increased risk of 
disability, disease, and premature death, due to 
obesity16 .  In Australia, from 1981 to 2000 the 
prevalence of obesity has been estimated to have 
increased from 8.1% to 20.5%, respectively17 .  This 
may place their direct health care costs and indirect 
costs above $1.5 billion dollars a year.  
Consequently, obesity has a major health and 
economic cost worldwide.  
 
Obesity and Mortality Rates   
 
While it is clear that obesity increases risk to a 
number of life threatening diseases, the link to 
mortality is less clear.  In this regard, throughout the 
history of medicine, the connection between obesity 
and mortality has been of considerable interest and 
debate.  There are four major methodological issues 
to consider when attempting to draw conclusions 
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from the literature in terms of the effects of obesity 
on mortality rates.  They include the following:  1.) 
the effects of smoking; 2.) the effect of pre-existing 
disease and weight fluctuation; 3.) the effect of 
physical inactivity; and, 4.) the lack of precision and 
accuracy in the use of BMI as an estimate of 
adiposity 18 .  Other potential confounding variables 
in associating obesity with mortality include:  age, 
race, family history, and the influence of weight loss 
on mortality19-21.  
   
Observational studies on the effects of weight loss 
show mortality rate decreases with obesity related co-
morbidities (e.g., diabetes).  However, in apparently 
healthy overweight/obese adults, intentional weight 
loss seems to neither decrease nor increase mortality 
rate.  Persons with lower levels of BMI are at a 
greater mortality risk than those with midrange 
BMI’s.  Some persons with low BMI are more likely 
to be sedentary, consume high fat foods and have 
lower aerobic fitness.  Thin people may also be 
consuming inadequate amounts of certain nutrients.  
In addition, individuals with lower levels of BMI 
may also be consuming inadequate amounts of 
certain nutrients.   According to Bray and Bouchard1  
a large scale, long-term, randomized controlled 
clinical trial is needed to examine this relationship.  
The authors recommend that such a study include:  
1.) a sample of persons along a broad range of BMI; 
2.) serial measures of body composition; 3.) thorough 
and ongoing clinical evaluations of health status; 4.) 
use of clinically relevant markers of sub-clinical 
disease as outcomes in addition to mortality as an 
endpoint.   
 
ETIOLOGY OF OBESITY 
 
Historically, obesity has been thought to simply be 
related to an imbalance between energy intake and 
expenditure.  However, more recent research has 
suggested that genetic, physiological, and behavioral 
factors also play a significant role in the etiology of 
obesity22 .  The following section will describe how 
excess energy intake, sedentary lifestyle, and genetics 
collectively lead to the state of obesity.   
 
Energy Intake 
  
Energy is consumed in the diet through protein, 
carbohydrate and fat intake.  In the presence of 
excess calories, the body will subsequently convert 
and store these energy nutrients as triglycerides in 
adipose tissue.  Over time, if excess calories are 
consumed without a concomitant increase in energy 
expenditure, excess body fat will be stored which 
may lead to obesity.  Excessive intake of energy 
nutrients has been reported to increase the size and 
number of adipocytes at various stages of the 
lifespan23 .  It has historically been thought that a 
calorie is a calorie and that the composition of 
isoenergetic diets would have no impact on weight 
gain or loss.  However, more recent research has 
indicated that not all of the macronutrients contribute 
to obesity in an equal manner.  For instance, a high 
fat meal that results in a positive energy balance will 
stimulate fat storage without a subsequent match in 
fat oxidation24, 25 .  Furthermore, the deposition of 
excess dietary triglycerides into adipose tissue is 
associated with a very low metabolic cost (0-2%)22  
whereas the thermic effect for carbohydrate and 
protein is 6-8% and 25-30%, respectively26 .  Thus, of 
the three macronutrients, protein requires the greatest 
metabolic cost to be converted to and stored as fat26. 
  
A number of studies have examined the effects of 
macronutrient intake at identical energy intakes on 
weight loss.  For example, Labayen and colleagues27  
studied the effects of a high protein hypo-caloric diet 
versus a high carbohydrate hypo-caloric diet in terms 
of subsequent weight loss.  The authors concluded 
that the replacement of some dietary carbohydrate by 
protein in energy restricted diets improves weight and 
fat losses by promoting lipid oxidation in the fasting 
state and sparring protein loss27 .  Similar results were 
found when obese participants consumed either an ad 
libitum high protein or high carbohydrate diet with 
fat intake kept constant in both groups (i.e., 30% of 
total energy)28 .  The authors found that the 
replacement of some dietary carbohydrate by protein 
in an ad libitum fat-reduced diet improves weight 
loss and increases the proportion of subjects 
achieving a clinically relevant weight loss.  Other 
studies have reported similar results in relation to the 
effectiveness and safety of a high protein diet29-31 .    
 
It should be noted that in long-term weight reduction 
diets, it appears that both standard protein (15% 
protein, 55% carbohydrate) or high-protein (HP; 30% 
protein, 40% carbohydrate) diets result in net weight 
loss and improvements in cardiovascular risk factors 
32, 33 .  The type of fat in the diet has also been 
reported to influence body mass.  For example, 
consumption of a diet rich in medium-chain 
triglycerides (MCT) results in greater loss of adipose 
tissue compared with long-chain triglycerides, 
perhaps due to increased energy expenditure and fat 
oxidation observed with MCT intake.  Hence, MCTs 
may be considered as agents that aid in the 
prevention of obesity or potentially stimulate weight 
loss 34 . 
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In addition to macronutrient influences, the volume 
of food intake may play a role in satiation and 
subsequent energy intake.  It has been shown that 
eating low-energy-dense foods like fruits and 
vegetables helps sustain satiety while concurrently 
reducing energy intake and appears to be a more 
effective weight loss strategy than fat reduction and 
decreased portion sizes 35 .  Fruits and vegetables are 
high in water and fiber, incorporating them in the diet 
can reduce energy density, promote satiety, and 
decrease energy intake36, 37 .  Epstein and colleagues38  
found that obese individuals that increased fruit and 
vegetable intake lost significantly more weight than 
those who restricted high fat/high sugar foods.  
 
Over recent years, researchers have explored how 
caloric and macronutrient intake affects gene 
expression.  When obese participants were assigned 
to one of two hypocaloric diets (20-25% fat or 40-
45% fat), they lost 7 kg over the ten-week duration of 
the study.  The researchers found that 10 genes were 
regulated by the energy restriction 39 .   Levels of 
peroxisome proliferator-activated receptor gamma 
co-activator 1alpha mRNA were increased, while the 
expression of the genes encoding leptin, osteonectin, 
phosphodiesterase 3B, hormone-sensitive lipase, 
receptor A for natriuretic peptide, fatty acid 
translocase, lipoprotein lipase, uncoupling protein 2 
and peroxisome proliferator-activated receptor 
gamma was decreased 39 .    The authors concluded 
that energy restriction rather than the ratio of fat to 
carbohydrate in a low-energy diet is important in 
modifying the expression of genes in the human 
adipose tissue.  It has also been shown that, a very 
low calorie diet (VLCD) significantly reduced 
adipose tissue mRNA levels of PPAR gamma and of 
leptin, but significantly increased TNF alpha mRNA 
levels 40 .  
  
Twin studies are often used to control for genetic 
differences among the participants and give insight 
into the true effectiveness of the intervention being 
studied.  For example, Faith et al.41  studied the 
effects of alterations in caloric intake and energy 
expenditure in monozygotic and dizygotic twins and 
reported that there may be macronutrient-specific 
familial influence.  Also, greater-than-average caloric 
intake was associated with increased levels of body 
fat, despite likely genetic influences on both 
phenotypes 41 .  In a related study, Tholin et al.37  
studied genetic and environmental influences on 
eating behavior in a large cohort of monozygotic and 
dizygotic twins.  The results of this investigation 
highlighted the importance of genetic factors in the 
eating behavior in young adult male twins.  In 
addition, it has recently been reported that the 
increase in the prevalence of obesity has 
concomitantly occurred with an increase in portion 
sizes of foods that we consume 35 .   
 
Energy Expenditure 
  
Energy expenditure is composed of basal metabolic 
rate, the thermic effect of food, and physical activity.  
Physical activity can also be broken down into two 
distinct sub-classes: (1) activity-related 
thermogenesis (volitional exercise); and (2) non-
activity related exercise thermogenesis (consists of 
all activity that one performs that is not related to 
“sporting-like” exercise)42 .  Activity thermogenesis 
accounts for approximately 15% to 50% of total daily 
expenditure in the sedentary to very active 
populations, respectively 43 .    It has been estimated 
that spontaneous minor activity performed during the 
day accounts for 20% of the differences of energy 
expenditure in a 24 hour time frame 44 .  Equally 
important, Castaneda et al.45  reported that minimal 
amounts of spontaneous physical activity are a major 
predictor of accumulating fat mass during 
overfeeding in humans.   It is also been shown in 
epidemiological studies that there is an inverse 
association between physical activity and weight46 .  
Similarly, Meredith et al.47  also reported that there 
was a negative association between aerobic exercise 
at 65 to 80% maximal oxygen uptake and body 
composition.  Additionally, a meta-analysis 
demonstrated that resistance training as well as 
aerobic exercise is effective in facilitating 
improvements in body composition, which may be 
due to the positive effects that resistance-training has 
in terms of increasing or maintaining lean mass 48 .  
Adding physical activity to promote weight loss 
encourages favorable changes in body composition.  
Sedentary lifestyle is commonly mentioned as a 
significant cause to the mounting prevalence of 
obesity.  In a recent study conducted by Slentz et al.49 
, researchers affirmed that those individuals who 
partake in a modest exercise program similar to the 
ones suggested by the Centers for Disease Control 
and the American College of Sports Medicine (e.g., 
at least 30 minutes of physical activity, on most days 
of the weeks, of moderate intensity, in one single or 
in multiple sessions), significant increases in health 
benefits can be expected.  In another study 50 , 
researchers looked at the comparison of monozygotic 
twins in relation to lipoprotein and weight variation 
between vigorously active and sedentary siblings.  
The authors reported that vigorous exercise could 
possibly reduce genetic influences on body mass 
index.  Increasing physical activity and energy 
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expenditure both prevents and treats obesity, but this 
recommendation is often not followed.  Hill and 
colleagues43  reported that 22-29% of adults don’t 
spend any time in leisure time physical activity.   
 
Possible Mechanisms 
 
In addition to the aforementioned causes of obesity, 
there are several hormones, genetic components, and 
secreted factors currently under investigation that 
have been implicated in the etiology of obesity.  
Some of these have an effect on long-term control of 
energy intake (e.g., leptin, neuropeptide Y) while 
others appear to have a short-term impact on energy 
intake (e.g., ghrelin, insulin, and cholecystokinin).  
The following overview discusses the role that 
several hormones, neuropeptides, and other factors 
may play in development of obesity.     
 
Insulin.  Insulin is an anabolic hormone, not only 
in regards to muscle, but also fat.  Insulin is known to 
direct the storage and utilization of energy in the 
adipocytes51 .  When an individual becomes insulin 
resistant, more insulin is subsequently secreted from 
the beta cells of the pancreas.  Abdominal obesity is 
related to insulin resistance and type 2 diabetes 52 .  
While increased body weight moderately reduces 
hepatic and peripheral insulin sensitivity, central 
obesity causes far greater impairments 53 .  Other 
hormones may play a role in the development of 
insulin resistance and obesity.  For example, leptin 
and adiponectin have been reported to increase 
insulin sensitivity.  Conversely, tumor necrosis 
factor-alpha (TNF-α) and resistin likely facilitate 
insulin resistance 54 .  Furthermore, leptin has been 
shown to decrease insulin secretion 55 .  The role that 
insulin, insulin sensitivity, and the control of insulin 
levels may play in the etiology of obesity is an area 
needing more research.    
 
Leptin. Leptin is a cytokine-like polypeptide 
produced by the adipocyte that controls food intake 
through the activation of hypothalamic receptors56 .  
Leptin is produced proportionately to the adipose 
mass and thus informs the brain of the fat store level.  
Upon binding to its receptor, activation of the Janus 
kinase/signal transducers and activators of 
transcription (JAK/STAT)  pathway is responsible 
for leptin’s effects57 .  Once leptin binds to its 
receptor (OB-R) in the hypothalamic arcuate nucleus, 
it induces the synthesis of α-melanocyte stimulating 
hormone (α-MSH) from the prohormone pro-
opiomelanocortin (POMC) through proteolytic 
cleavage mediated by the enzyme pro-hormone 
convertase (1PC-1).  Subsequently, α-MSH binds to 
the melanocortin 4 receptor (MC4R) in the 
paraventricular nucleus which inhibits the effectors 
of food intake56 .   
  
When leptin is injected into leptin deficient animals, 
it results in decreased food intake and subsequent 
weight loss and the maintenance of weight loss.  
Obese humans do not have a deficiency of leptin, but 
surprisingly have higher levels of circulating leptin in 
the body.  This would indicate that leptin deficiency 
is not a primary cause of obesity, but rather a 
decreased response to leptin.  Several theories have 
been postulated in relation to this unresponsiveness to 
circulating plasma leptin levels.  First, there appears 
to be a threshold plasma leptin concentration (~ 25 
ng/ml) above which the uptake of leptin into the 
hypothalamus does not increase anymore in spite of 
high values of leptin (i.e. leptin receptor saturation).  
Thus, in patients with morbid obesity, an increase in 
leptin production by the enlarged fat mass would be 
futile 58 .  Second, there may be defect in the 
hypothalamic leptin receptor OB-R.  Finally, there 
may be a defect in the leptin signaling cascade.  
Some of these defects may include genetic mutations 
in POMC, PC-1, and MC4-R (all are involved in the 
leptin signaling cascade described above).  In reality, 
most obese individuals do not have a defect in the 
leptin receptor59 .  The determination of whether 
defects in the leptin signaling cascade plays a role in 
the development of obesity needs further research.   
 
Neuropeptide Y.  Closely related to impaired 
leptin function and its effects on energy intake is the 
role of neuropeptide Y.  Neuropeptide Y is one of the 
most potent stimulators of food intake 60 .  Leptin 
(when functioning properly) modulates the 
expression of neuropeptide Y that helps to control the 
drive to consume excess food.  Neuropeptide Y and 
leptin do not appear to be the only factors responsible 
for the control of energy intake.  It is likely that 
neuropeptide Y and leptin interact with other 
regulatory peptides in a yet unexplained fashion 22 .  
As stated above, neuropeptide Y stimulates food 
intake.  In a recent study examining the role of 
neuropeptides in the control of appetite, it was 
observed that the highest plasma neuropeptide Y 
levels were found in obese hypertensive and diabetic 
patients 61 .   
 
Cortisol.  Cortisol is a glucocorticoid known to 
have powerful metabolic effects.  These include 
mobilization of fatty acids from stored triglycerides, 
hepatic gluconeogenesis, and proteolysis.  Epel et 
al.62  studied fifty-nine healthy pre-menopausal 
women, their cortisol levels and subsequent eating 
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patterns to both a session where stress was induced 
and a control session on various days.  The study 
revealed that the women who had high cortisol 
secretions in response to the stress session ate larger 
quantities of food and significantly more sweet foods 
62 .  It is commonly known that people who are 
suffering from Cushing syndrome have elevated 
levels of cortisol secretion and associated visceral or 
abdominal fat 63, 64 .  Therefore, it appears that an 
excessive amount of cortisol leads to an increase in 
the storage of abdominal fat.  In addition, a review 
article by Bjorntorp et al.63  makes it clear that there is 
an association between hypercortisolemic states and 
obesity which appears to be related to a hypothalamic 
dysfunction.  Equally important, it seems that the 
hypothalamic-pituitary-adrenal (HPA) axis works in 
concert with acute increases in insulin after feeding 
in both humans and rats 65 .  This synergistic action 
could possibly lead to increases in visceral adipose 
tissue storage 65 .  Researchers have found an 
association between central body fat, perceived stress 
and elevated cortisol levels 63 .  However, it is still 
unclear whether cortisol abnormalities are a cause or 
merely a result of obesity.    
 
Ghrelin.  Ghrelin, a growth hormone 
secretagogue, is highly concentrated in the stomach.  
Gastric ghrelin expression and secretion increases 
with fasting (and hence stimulate feeding) and 
declines in the postprandial state 66 .  Surprisingly, 
reduced plasma ghrelin concentrations have been 
reported in human obesity 53 .  The effect of ghrelin 
on weight is probably mediated through central 
antagonism of leptin and other anorectic cytokines 
through signals delivered via vagal afferents, rather 
than a direct blood borne effect on the hypothalamus 
67 .  This action may be mediated through increased 
expression of hypothalamic neuropeptide Y 67 .  In 
addition to stimulating feeding, ghrelin is involved in 
the regulation of growth hormone secretion.  Further 
research should clarify the extent to which these 
actions are distinct or intrinsically related.   
 
Norepinephrine, Serotonin, Interleukin-6 and 
TNFα.  Other biological factors have been shown to 
influence energy intake and possibly contribute to 
obesity.  Norepinephrine both stimulates and 
decreases food intake depending on which type of 
receptor it interacts with.  When it acts on α-1 
adrenoreceptors in the paraventricular nucleus (PVN) 
it decreases food intake.  Conversely, when 
norepinephrine acts on α-2 adrenoreceptors in the 
PVN it results in the stimulation of food intake 68 .  
Serotonin works in a similar fashion.  Stimulation of 
the 5HT1A receptor by serotonin acutely stimulates 
food intake, but this response rapidly attenuates.  
Reduction in food intake by serotonin probably 
occurs by action on the 5-HT2C receptor 68 .  
Interleukin-6 (IL-6) that circulates through the blood 
has been reported to be correlated with BMI 69 .  
Trujillo and colleagues 70  reported that adipose tissue 
IL-6 expression is increased in obesity and is a strong 
predictor of abnormalities in adipocyte and systemic 
metabolism.  Equally important, IL-6 may modulate 
leptin production and lipid metabolism in human 
adipose tissue 70 .  Tumor necrosis factor alpha 
(TNFα) has been reported to stimulate IL-6 
production from the adipose tissue P80 receptors that 
contribute to adipocyte differentiation and may play a 
role in the inhibition of leptin 71 .  In an investigation 
studying obese children, TNFα concentrations were 
significantly higher than in controls 72 .  
 
Other Hormones Implicated in Obesity.  
Testosterone reduces lipoprotein lipase activity and 
increases lipolysis in males, but in females these 
effects are counteracted by estrogen 71 .  Testosterone 
has also been reported to regulate leptin mRNA 
expression 71 .  The growth hormone/insulin like 
growth factor axis (GH-IGF-1 axis) is an important 
regulator of body composition.  Multiple GH-IGF 
axis defects are present in obese individuals1 .  
Evidence suggests that growth hormone is an 
important hormone in lipolysis 73 .  Not all of growth 
hormone’s effects are mediated through IGF-1 
however.  Hansen 74  reports that growth hormone 
stimulates lipolysis, protein synthesis and indirectly 
inhibits proteolysis through IGF-1.   Another 
hormone that had been thought to be related to 
obesity is thyrotropin stimulating hormone (TSH).  
Iacobellis et al. 75  reported that TSH and BMI were 
positively related and TSH has been found to be 
correlated with leptin adjusted for BMI.   However, 
the interest surrounding thyroid hormones as a 
treatment for obesity may not be supported by 
research.  In one study, the authors concluded that 
there appears to be no place for T3 as an adjunct to 
dieting, since it mostly enhances body protein loss 
and has only minimal effects on body fat loss 76 .  
Corticotropin-releasing hormone (CRH) may act 
through CRH-2 receptors to reduce food intake 77 .  
Melanocyte-stimulating hormone may be another 
important modulator of feeding, because it has been 
shown in mice that damage to the melanocortin-4 
receptor in the hypothalamus leads to massive obesity 
78 .   
 
Other Peptides Implicated in Obesity .  The list 
of peptides that stimulate or suppress food intake 
continues to grow.  Peptides that stimulate food 
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intake include neuropeptide Y (described above), 
melanin-concentrating hormone (MCH), and growth 
hormone releasing hormone (GHRH) 79 .  The list of 
inhibitory peptides includes cholecystokinin (CCK), 
which decreases food intake centrally as well as 
peripherally.  This was confirmed in a study 
conducted by Brennan and collegues 80 .  In this 
study, CCK increased fullness and decreased 
subsequent energy intake.  Lastly, enterostatin is a 
particularly interesting peptide because it is derived 
in the gastrointestinal tract and specifically reduces 
fat intake 68 .   
 
 Metabolic Syndrome.  Metabolic Syndrome is 
characterized by a group of metabolic risk factors 
that include the following:  central obesity 
(excessive fat tissue in and around the abdomen); 
atherogenic dyslipidemia (blood fat disorders, 
mainly high triglycerides and low HDL cholesterol; 
raised blood pressure (130/85 mmHg or higher); 
insulin resistance or glucose intolerance (the body 
can’t properly use insulin or blood sugar); 
prothrombotic state (e.g., high fibrinogen or 
plasminogen activator inhibitor [–1] in the blood); 
and, proinflammatory state (e.g., elevated high-
sensitivity C-reactive protein in the blood) 81 .  The 
combination of insulin resistance, abdominal 
obesity, dsylipidemia, and hypertension are all 
established risk factors for cardiovascular disease, 
type 2 diabetes mellitus and stroke.  Insulin 
resistance, visceral fat, and hormones are primary 
pathological factors in Metabolic Syndrome.  
Research findings suggest a quantitative connection 
between cortisol secretion and metabolic syndrome 
63 .  One particularly powerful affect of cortisol is its 
ability to cause peripheral insulin resistance.  
Cortisol secretion is vulnerable to regulatory errors 
of the hypothalamic-pituitary-adrenal (HPA) axis.  A 
number of factors are known to stimulate the stress 
centers indirectly in the metabolic syndrome.  They 
are classified as environmental stressors, stimulant 
usage, and physiologic events 81 .  Other physiologic 
elements that correlate to metabolic syndrome 
include: aging, cytokines and small baby syndrome1 .  
Genetics play a large role in metabolic syndrome.  
The primary genes and pathways responsible include 
the aromatase gene, leptin receptor gene, 
proopiomelanocortin (POMC) gene, serotoninergic 
system, and the HPA axis genes corticotrophin-
releasing hormone (CRH) and the GR gene.  Our 
current societal environment seems to also play a 
role in metabolic disorder scenarios due to a 
competitive society, exposure to excessive energy-
dense food, and physical inactivity.     
  
In summary, research indicates that the etiology of 
obesity is multi-factorial and is evident in the 
abnormal levels of many biological molecules 
(Figure 2).  Genetic, physiological, and behavioral 
factors all play a significant role in the etiology of 
obesity.  While no single cause has been attributed to 
obesity, it is likely that each of the aforementioned 
theories all contribute to the state of obesity.  In 
addition to the physiological abnormalities, there are 
medical consequences associated with obesity.   
 
MEDICAL CONSEQUENCES OF OBESITY 
 
There is little question that substantial excess 
adiposity increases mortality.  The prevalence of 
overweight and obesity continues to rise and is 
reaching epidemic proportions in developed and 
developing countries.  Due to the strong association 
of obesity and cardiovascular disease, type 2 
Diabetes, and other chronic diseases, this trend 
suggests a substantial increase in obesity-related 
morbidity and mortality for the future.  Public health 
approaches must focus on interventions that would 
educate the public on the dangers of poor lifestyle 
choices and their subsequent outcomes. 
 
Cardiovascular Disease, Coronary Heart Disease, 
Hypertension, and Congestive Heart Failure 
 
Obesity is classified as a risk factor for 
cardiovascular disease (CVD) because of its effects 
on cardiac structure.  In obese and overweight 
individuals, the cardiac structure and function 
changes as a result of an increase in total plasma and 
blood volume.  These changes occur due to an 
increase in blood volume, which results in increased 
LV filling, an increase in stroke volume (SV), and 
finally an increase in absolute cardiac output (Q).  
This increase in Q is solely due to a structural 
change, and is not influenced by heart rate (HR), as 
HR remains unchanged 82 .  Although there is an 
increase in absolute Q, when normalized to body 
surface area, Q remains unchanged.  Over time, these 
structural changes result in the LV increases in 
myocardial wall stress, which then causes myocardial 
growth in the LV.  The effects of obesity and 
overweight affect cardiovascular disease from several 
different angles, including arrhythmias, peripheral 
vascular disease (PVD) and stroke, sudden death, 
coronary heart disease (CHD) and atherosclerosis, 
and most predominantly hypertension and congestive 
heart failure (CHF). 
 
Atherosclerosis develops through a progression from 
plaque formation to plaque rupture, formation of a 
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thrombus, and then finally to fibrosis 83 .  Obesity and 
distribution of body fat to the abdominal area have 
been linked to the promotion of plaque build up and 
atherosclerosis.  There are several other risk factors 
for CHD that are associated with obesity, including 
diabetes, insulin resistance, dyslipidemia, 
hypertension, LV hypertrophy, endothelial 
dysfunction, chronic inflammation, and obstructive 
sleep apnea 1 .  Despite these risk factors, there has 
been no establishment of a consistent relationship 
between obesity and CHD because of several 
problems with distribution of body fat, smoking 
status, and the use of inappropriate control 
populations 84, 85 .  Although obesity does not present 
a consistent relationship, body fat distribution has 
been shown to be related to CHD.  Specifically, 
increased fat distribution in the abdomen has been 
shown to increase CHD regardless of body weight 86, 
87 .         
  
Hypertension and CHF in obese individuals is most 
often directly related to LV hypertrophy.  It has been 
noted that there is a strong association between 
hypertension and obesity in both genders, all age 
groups, and in almost all ethnic groups 88, 89 .  Fat 
distribution, including upper-body obesity or 
increased abdominal fat, serve as better predictors of 
hypertension than BMI alone90 .   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.  Adapted from Chapter 25 – Endocrine Determinants of Obesity.  Handbook of Obesity – Etiology and Pathophysiology. 
Second Edition. Edited by George Bray and Gary Bouchard.  p.663, figure 2. 
 
 
There are several mechanisms in which obesity might 
cause hypertension.  Insulin resistance 91 , enhanced 
sodium retention 92 , and increased activation of the 
sympathetic nervous system 93  are all among the 
most researched possible mechanisms.  Other 
mechanisms include alterations in vascular structure 
and function (linked with insulin resistance) 94, 95 , 
alterations in ion transport, serum leptin levels 96, 97 , 
and actions of the hypothalamus.  Long-term obesity 
is associated with LV dilation and impaired systolic 
function with CHF frequently being the ultimate 
cause of death. 
  
Most research indicates that weight loss in 
overweight and obese individuals improves CHD risk 
factors such as blood glucose and insulin 
concentrations 98 , blood lipids 99 , and blood pressure 
99, 100 .  Weight loss has also shown to improve 
cardiovascular abnormalities such as dyslipidemia, 
LV hypertrophy, and structural abnormalities in both 
adults and adolescents.  Specifically, endurance 
training has been shown to be the most beneficial 
mode of exercise for decreasing cardiovascular risk 
factors because it enhances an increase in capillary 
density and muscle oxidative capacity 101 .     
 
Arrhythmias 
 
Messerli and colleagues 102  found that ventricular 
ectopy occurred ten times more often in obese 
individuals than normal weight individuals.  Obesity 
has also been shown to promote risk factors for 
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arrhythmias including sleep apnea, CHD, LV 
hypertrophy, and autonomic imbalance 102, 103 .  The 
most commonly noted arrhythmias include sinus 
arrhythmia, premature ventricular complexes, 
premature atrial complexes, ventricular tachycardia, 
and supraventricular tachycardia 1 .  Collectively, 
these findings indicate that obesity increases the risk 
of arrhythmia.   
 
Stroke and Peripheral Vascular Disease  
 
The role of obesity and overweight in stroke and 
PVD is based on the increased risk of ischemia and 
atherosclerosis 87, 104 .  However, the effect of obesity, 
independent of other risk factors, on stroke and PVD 
does not have consistent support 104, 105 .  Excess body 
fat is associated with the thickening of only carotid 
arteries, and thus, obesity alone does not appear to 
increase the risk for stroke or PVD 100, 106 .  
 
Sudden Death 
 
Autopsy results of obese sudden death patients show 
that ventricular hypertrophy is the most common 
finding 1 .  The three-generation Framingham Heart 
Study has shown that the sudden death is predictive 
for overweight and obese men and women based on 
the degree of overweight 88 . This factor predicts 
independently of other CHD risk factors.  The 
Framingham Heart Study also showed that obese 
individuals with CHF have a fivefold increased risk 
of sudden death compared to the general population 
107 .   
 
Diabetes 
 
Approximately 85% of diabetics fall into the type 2 
category and of these 70% are overweight, with a 
BMI of 30 or greater.  It has been reported that the 
prevalence for type 2 diabetes is approximately 5 
times higher for men and 8.3 times higher for women 
in obese groups compared to normal weight 
individuals.  Furthermore, a gain in weight of 7.0-
10.9 kg after the age of 18 years leads to a twice the 
risk for developing diabetes.  The rate of type 2 
diabetes has also risen in adolescents with physicians 
reporting one-third to one-half of new diabetic cases 
being type 2 108 .    The diabetes epidemic is on the 
rise on a worldwide level especially in non-European 
countries.  Along with a genetic disposition, 
sedentary lifestyle, poor nutrition, and obesity are 
attributed to this problem.  It has been demonstrated 
that obesity, especially central obesity, is associated 
with diabetes.  In the United States, the Pima Indians 
have the highest incidence of diabetes with Mexican 
Americans having the second highest.  Waist to hip 
ratio is often used to determine the presence of 
central obesity, but it appears that the waist 
circumference alone may be a better indicator of 
insulin resistance and central obesity than the waist to 
hip ratio.  Obesity can lead to insulin resistance, 
which may be attributed to in part by concomitant 
increases in circulating free fatty acids in the blood 
stream.  Additionally, glucose intolerance is also 
associated more with central obesity.  It has more 
recently been postulated that cytokines like TNFα, 
which correlate with obesity, may be a player in 
developing insulin resistance and Il-6 may be related 
to insulin sensitivity as well.  Resistin and 
adiponectin may also pay a role in insulin resistance.  
It also has been established that diabetes can increase 
cardiac risk factors.  The management of the obese 
diabetic patient should first include glycemic control 
and weight loss via caloric restriction and/or exercise 
with long-term maintenance goals.  A loss of just 5-
10% of the subject’s initial body weight significantly 
improves the HgbA1c value, decreases blood 
pressure, and improves lipid profiles 109-111 .  If weight 
loss is not possible through conventional means, 
pharmacological interventions (i.e., sibutramine, 
orlistat and thiazolidinediones) and surgery may be 
efficacious 111 .  
 
Gallbladder Disease 
 
Gallstones have a higher prevalence rate among 
obese populations and those losing weight.  The 
gallstone formation requires two conditions:  
secretion of supersaturated bile and gallbladder stasis.  
Obesity directly affects bile composition and 
gallbladder motility.  In obesity, bile is more 
saturated due to cholesterol hypersecretion, which 
leads to the impairment of  gallbladder motor 
function 1 .  Research has recently suggested that 
leptin may mediate the association between obesity 
and gallstones 112 .  The incidence of gallstones in 
obese women has been estimated at 2.6 per 100 
person-years 113 .  The relationship between obesity 
and gallstones is less impressive but research has 
shown an increased risk of gallstones in men with 
increasing BMI 114 .  Men and women undergoing 
bariatric surgery have as high as a 43% incidence of 
gallbladder disease, defined as prior cholecystectomy 
or gallstones.  Normal pathology was more common 
in male patients 80% vs. 63%) 115 .  Ursodeoxycholic 
acid is the only medical therapy studied for gallstones 
during weight reduction 116 .   Further research is 
needed in this area as well as in the area of weight 
reduction and the formation of gallstones. 
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Arthritis 
 
Obesity is an important risk factor for osteoarthritis 
and gout.  These health conditions are an important 
area to research due to the significant morbidity and 
cost to the community.  Musculoskeletal conditions 
are the cause of a larger percentage of acute and 
chronic disability, the most common cause of work 
disability.  There has been a consistent relationship 
between osteoarthritis (OA) and obesity.  Obesity is a 
potential modifiable risk factor for this very 
expensive problem.  There are several possible 
mechanisms that explain the association between 
obesity and osteoarthritis.  Some of these include 
increased joint load and indirect metabolic changes.    
Other metabolic conditions that may be involved with 
the development of osteoarthritis include: 
hypertension, abnormal cholesterol and blood 
glucose levels, and uric acid 1 .  Recent research 
suggests a link between these disorders and 
osteoarthritis, but the data are is inconclusive at this 
time 117 .   The adjusted risk of knee osteoarthritis was 
increased fourfold in men with a current BMI 23 to < 
25 kg/m2 as compared to men with BMI < 23 kg/m2.  
BMI at 30 years of age was similarly related to knee 
osteoarthritis. These researchers concluded that a 
moderate increase in BMI, within the normal weight 
range, was significantly related to knee osteoarthritis 
among men.  Being overweight at any time was 
related to knee osteoarthritis 118 . 
 
Pregnancy and Infertility 
 
Obesity can affect fertility due to hormonal 
alterations that include: increased levels of 
gonadatropins and androgens which may cause 
anovulation, reduction in sex-hormone-binding 
globulin (SHBG), and increasing biologically active 
free androgens which are  associated with 
anovulation.  Obesity after pregnancy results in 
pronounced and sustained weight gain in many 
women and can be viewed as an example of weight 
cycling.  The factors affecting variation in weight 
gain are maternal characteristics such as age, pre-
pregnancy weight, parity (i.e., number of children 
borne by one woman) ethnic origin, and various 
aspects of socioeconomic status, drug abuse, and 
physical activities levels.  The Stockholm Pregnancy 
and Weight Development Study showed 73% of 
women retained > 10 kg of bodyweight up to one 
year after delivery 119 .  In relation to infertility, a 
recent study concluded that infertile women with an 
abnormal body mass and FSH levels significantly 
decrease the chance of pregnancy .  Infertile women 
are advised that their chances of assisted reproduction 
treatment would increase with weight loss.  
Researchers have also used subscapular thickness 
ratio (SSTR) in determining the health of offspring in 
the obese population.  Their findings showed that 
maternal truncal obesity rather than thinness is 
associated with raised blood pressure in the offspring, 
and that the link may be mediated by increased 
cortisol secretion 120 .          
 
Sleep Disorders  
 
Global population studies suggest that the syndrome 
of obstructive sleep apnea, daytime sleepiness, and 
cardiovascular disease is present in approximately 1-
4% of working men and women 121 .  The prevalence 
rate is higher in minority populations and children 
with tonsilar hypertrophy.  However, one of the best-
characterized associations are between obesity and 
Obstructive Sleep Apnea (OSA).  Weight gain and 
loss can affect the severity of this disorder.  A weight 
gain of as little as 10% has predicted a six-fold 
increase in the odds of developing moderate to severe 
sleep-disordered breathing.  A loss of 10% body 
weight predicted a 26% decrease in the apnea-
hypopnea index 122 .  Approximately 10-15% of 
morbidly obese patients may develop a disorder of 
the respiratory control system manifested by CO2 
retention during wakefulness.  This disorder is called 
obesity-hypoventilation syndrome (OHS).  The exact 
mechanism of this disorder has yet to be explained.  
Aside from the obesity link, other potential 
explanations for this disorder include:  genetic 
variations in ventilatory responses, interactions 
between the metabolic effects of obesity and 
respiratory control, and/or effects of comorbid 
cardiovascular or metabolic events also linked to 
obesity acting on respiratory control 123 .  The current 
management strategies for OSA and OHS include 
weight loss through diet and exercise, anorexiant 
drugs, and surgically induced weight loss.  The 
current adjunct treatments to weight loss include: 
noninvasive ventilation referred to as continuous 
positive airway pressure (CPAP), pharmacological 
treatment of daytime symptoms of drowsiness, 
tracheotomy, supplemental oxygen and treatment of 
coexisting pathology such as congestive heart failure 
121 .  Current research in sleep disorders is elucidating 
the association the role sleep plays in energy 
homeostasis.  Researchers have analyzed associations 
between sleep duration and leptin and sympathovagal 
balance, cortisol, TSH, glucose, and insulin.  The 
findings support that sleep modulates a major 
component of the neuroendocrine control of appetite 
124 .  Another study looked at sleep deprivation and its 
association with hyperphagia.  These scientists 
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concluded that short sleep deprivation in young, 
healthy males was associated with decreased leptin 
levels and increased ghrelin levels, with subsequent 
increased hunger and appetite 124 .           
 
Quality of Life 
 
The health consequences and psychosocial problems 
associated with obesity often have an adverse effect 
on quality of life.  The consequences of these co-
morbidities and conditions obviously increase the 
likelihood of higher rates of disability in this group of 
people.  There is a complex relationship between 
obesity and disability.  Sedentary lifestyle contributes 
to obesity and obesity exacerbates disability 125 .  
Limitations in everyday functioning of overweight 
and obese people are the consequence of co-
morbidities (e.g., peripheral vascular complications 
and end organ diabetic diseases).  The leading cause 
of disability is impairment of the musculoskeletal 
system caused by excessive weight (e.g., chronic low 
back and lower extremity pain).  Morbidly obese 
people have also been shown to have a lower quality 
of life.  The Gastrointestinal Quality of Life Index 
(GIQLI) test was issued to determine the quality of 
life in morbidly obese patients.  These patients have a 
poorer quality of life due to the presence of digestive 
symptoms as well as issues surrounding their 
emotional, physical, and social status 126 .   
 
BEHAVIORAL AND MEDICAL 
MANAGEMENT OF OBESITY 
 
Behavior Management Models 
 
The energy imbalance leading to overweight and 
obesity is usually caused by behaviors that lead to 
increased food intake or decreased energy 
expenditure 127 .  Behavioral modification is the 
application of learning theory to obesity treatment 
and has been a standard therapeutic strategy in the 
treatment of obesity for both adults and children for 
the last 25 years 68 .  Behavior modification is 
recommended as one of the first approaches to 
obesity treatment but if it is not successful, medical 
treatments such as pharmacological or surgical 
treatments used in conjunction with behavior 
modification may be necessary.   
 
Behavioral intervention is usually made by a 
psychologist, behavioral therapist, dietician, or 
exercise physiologist and treatment encourages 
individuals to make healthier lifestyle choices by 
including dimensions of increasing physical activity 
and modifying eating habits 127 .  There are many 
models for behavior modification including operant 
conditioning, Pavlovian conditioning, 
psychoanalysis, cognitive behavioral therapy, and the 
transtheoretical approach.  The most successful 
models include self-monitoring and stimulus control.  
The operant conditioning model includes recording 
behavior related to activity and food intake, which 
includes dimensions of mood and context.  Good 
behavior is rewarded to increase the frequency of 
desired behavior 68 .  Strategies emphasize making 
small, but sustainable changes 127 .  Pavlovian or 
classical conditioning emphasizes changing 
association patterns, between two stimuli 68 .  Refer to 
table 1 for definitions related to behavioral 
management techniques related to obesity.   
  
In a statistical analysis of the records of a 
commercial, noncommercial, and medical weight-
reducing organizations, researchers indicated that 
reducing caloric intake, aided by financial incentives 
and supportive group pressures, is suggested as the 
basis for weight loss success in commercial weight-
reducing organizations 128 .  It should be noted that 
between 1999-2000 and 2001-2002, there were no 
significant changes among adults in the prevalence of 
overweight, obesity, or extreme obesity, or among 
children aged 6-19 years in the prevalence of at risk 
for overweight 129 .Thus, it seems that preventive 
measures have been somewhat successful. 
  
A multidisciplinary weight management program 
based on the Transtheoretical Model, focusing on a 
healthy lifestyle rather than weight loss, was applied 
in a 6-month clinic-based weight management 
program.  The study included 144 overweight and 
obese adults.  The first 3 months of the program 
included intense intervention twice weekly for two 
hours followed by 3 months of reduced clinical 
contact.  Subjects experienced significant decreases 
in weight, percentage body fat, BMI, total 
cholesterol, LDL-C, total caloric intake, and the 
percentage of energy intake from dietary fat as well 
as a significant increase in VO2max (P < 0.05) at 3 
months.  Changes were maintained at 6 months, with 
further improvement in weight, total cholesterol, and 
LDL-C 130 .  Also, cognitive-behavioral treatment can  
be used to help overweight adolescents become more 
assertive in coping with the social stigma of being 
overweight, enhance their self-esteem, and reduce 
their dissatisfaction with body image regardless of 
weight loss 131.  Overviews of behavioral and medical 
approaches in the management of obesity are 
included in the following section. 
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Table 1.  Definitions of behavioral management of obesity techniques 
TREATMENT DEFINITION 
Behavioral modification Behavioral management techniques such as self-monitoring, stimulus 
control, eating management, rewarding behavior, etc. 
Multimodel Approach Approach that involves 6 steps.  The first step is self-monitoring followed by 
control over eating, adding exercise, controlling self-talk, involving social 
support, and relapse prevention. 
Psychotherapy Traditional psychotherapy techniques such as humanistic therapy, or 
psychodynamic therapy which addresses unconscious motives.  For 
example, an individual may unconsciously overeat to emotionally insulate 
themselves. 
Cognitive- behavior therapy Cognitive approaches such as rational emotive behavior therapy or cognitive-
behavior therapy. Therapy is a collaborative process of empirical 
investigation, reality testing, and problem solving and focuses on the beliefs 
that people hold of their health habits.  An example is controlling self-talk. 
Pavlovian Conditioning or  Classical 
Conditioning 
Behavior patterns involve the association between unconscious reflexes with 
new stimuli that can be transferred to a conditioned response.   
Operant Conditioning Technique that pairs a voluntary behavior with systematic consequences.  
Reinforcement should occur when positive behavior occurs.  Intermittent 
reinforcement schedules are more resistant to extinction.  An example would 
be to reinforce participants in a research study when they come in for testing. 
Self-monitoring The participant monitors their own behavior or activities.  This can include 
food and activity logs.   
Stimulus control Strategies designed to alter cues leading to inappropriate eating, such as 
eating while watching television. 
Eating management Techniques specifically aimed at modifying the act of eating, such as eating 
slowly and drinking water before meals. 
Lifestyle exercise Increased daily lifestyle activity such as taking stairs instead of elevators, 
walking to the store instead of driving, etc. 
Self-efficacy A person's belief that he or she has the behavioral skills to cope successfully 
with high-risk situations.  
 
Behavioral Modification of Food Intake 
 
Behavioral interventions designed to promote dietary 
change include the following: medical  
assessment, assessment of diet history, assessment of 
readiness, establishment of dietary goals, self-
monitoring, stimulus control training, training in 
problem solving, relapse prevention training, 
enlistment of social support, nutrition education, 
dietary therapy, and ongoing support to maintain 
progress 131 . Examples include regular pattern of 
meals including breakfast, controlled portion size, 
elimination of second helpings, elimination of high 
calorie drinks and snacks, decreased frequency of 
eating out, and eating meals with family members at 
a slow pace of eating.  Food should never be used as 
a reward 127 .  The suggestion to change dietary habits 
is considered behavioral modification 132 . 
 
Dietary Intervention  
 
In addition to these behavioral techniques, many diets 
are available.  The three largest nonmedical 
commercial programs in the United States are Weight 
Watchers, Jenny Craig, and LA Weight Loss 133 .  
However, LA Weight loss does not have any reported 
research.  The following overviews the reported 
efficacy of some common diets studied purported to 
promote weight loss.  
 
American Heart Association.  The American 
Heart Association 108  has offered the following 
dietary guideline: 
1. Total fat intake should be less than 
30% of energy  
2. Saturated fat intake should be less than 
10% of total energy  
3. Polyunsaturated fat intake should be 
no more than 10% of total energy  
4. Monounsaturated fat intake should 
make up the rest of total fat intake, 
about 10% to 15% of total energy 
5. Cholesterol intake should be no more 
than 300 mg/d 
6. Sodium intake should be no more than 
3000 mg (3 g) per day  
In addition, the AHA dietary guidelines include the 
following recommendations for food selection: 
1.    No more than 5-8 teaspoons of fats and 
oils per day, including the fats used in 
cooking and baking and in salad 
dressings and spreads  
2.    Six ounces or less of lean meat, fish, or 
skinless poultry  
3.    No more than three or four egg yolks per 
week  
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4.    Two to four servings of nonfat or low-fat 
milk and dairy products per day  
5.    Five or more servings of fruits and 
vegetables per day  
6.    Six or more servings of breads, cereals, 
rice, pasta, other grains, and starchy 
vegetables per day  
Weight Watchers.  Weight Watchers was founded 
in 1961 by Jean Nidtech.  There have been three 
randomized controlled trials investigating its 
effectiveness.  Individuals responding (n = 985) to 
newspaper advertisements in two metropolitan areas 
were assigned to 4 weeks of either the Weight 
Watchers program or to a Self-Help condition.  
Weight loss, psychological vitality, and eating 
behavior were evaluated before and after a four week 
intervention.  Results indicated that Weight Watchers 
participants showed greater improvements than Self-
Help participants did on all measures and weight 
losses averaged 1.87 and 0.77 kg respectively.  The 
outcomes shown by Weight Watchers participants on 
measures of vitality and eating behavior were still 
evident when extent of weight loss was controlled 
across different sites, incomes, and levels of obesity 
134 .   
 
A 2-year, multicenter randomized clinical trial with 
clinic visits at 12, 26, 52, 78, and 104 weeks was 
conducted at six academic research centers in the 
United States between January 1998 and January 
2001.  Participants included overweight and obese 
men (n = 65) and women (n = 358) with BMI 27-40 
aged 18 to 65 years.  Random assignment to either a 
self-help program (n = 212) consisting of two 20-
minute counseling sessions with a nutritionist and 
provision of self-help resources or to Weight 
Watchers (n = 211) consisting of a food plan, an 
activity plan, and a cognitive restructuring behavior 
modification plan, delivered at weekly meetings.  
Weight change was the primary outcome measure.  
Secondary outcomes included waist circumference, 
BMI, blood pressure, serum lipids, glucose, and 
insulin levels 10 . 
  
Changes in serum homocysteine levels measured in a 
subsample of participants during the first 12 weeks.  
Results were reported after 26 weeks.  Participants in 
Weight Watchers had greater decreases in body 
weight [mean (± SD) -4.8±5.6 vs -1.4±4.7 kg] and 
BMI (-1.7±1.9 vs -0.5±1.6 kg/m (2), both P<0.001) 
compared with those in the self-help program.  
Among subjects measured at week 26, mean waist 
circumference (-4.3±10.5 vs -0.7±12.7 cm) and fat 
mass (-3.8 ±7.0 vs -1.5±7.6 kg, both P<0.05) also 
decreased more among subjects in Weight Watchers.  
Mean serum homocysteine levels improved in 
Weight Watchers compared with self-help (-0.5±1.3 
vs 0.9±1.8 microM, P<0.05), indicating that for 
managing moderately overweight patients Weight 
Watchers is more effective than brief counseling and 
self-help 135 . 
  
At 2 years, 150 participants (71%) in Weight 
Watchers and 159 (75%) in the self-help group 
completed the study.  In the intent-to-treat analysis, 
mean (SD) weight loss of participants in the 
commercial group was greater than in the self-help 
group at 1 year (-4.3 ± 6.1 kg vs -1.3±6.1 kg, 
respectively; P<.001) and at 2 years (-2.9 ±6.5 kg vs -
0.2 ±6.5 kg, respectively; P<.0001).  Waist 
circumference (P =0.003) and BMI (P<0.001) 
decreased more in the commercial group.  Changes in 
blood pressure, lipids, glucose, and insulin levels 
were related to changes in weight in both groups, but 
between-group differences in biological parameters 
were mainly nonsignificant by the second year.  
Authors concluded that structured commercial weight 
loss programs provided modest weight loss, but more 
than self-help programs 10 . 
  
Weight loss maintenance among participants in 
Weight Watchers who had reached their goal weights 
1-5 years previously were studied in a national 
sample (n=1002).  Participants were surveyed by 
phone to obtain demographic and weight-related 
information.  An over sample (n=258) was recruited 
and weighed in person to develop a correction factor 
for self-reported weights in the national sample.  
Results indicated that weight regain from one to 5 
years following weight loss ranged between 31.5 and 
76.5%.  At 5 years, 19.4% were within 5 lb of goal 
weight, 42.6% maintained a loss of 5% or more, 
18.8% maintained a loss of 10% or more, and 70.3% 
were below their initial weight.  The authors 
concluded the long-term prognosis for weight 
maintenance among individuals who reach goal 
weight in Weight Watchers is better than that 
suggested by existing research 134 . 
 
Jenny Craig.  The Jenny Craig weight loss 
program was founded by Sid and Jenny Craig in 
Australia in 1983 and the first Jenny Craig opened in 
the United States in 1985 136 .  The program requires a 
client to purchase the company’s prepackaged meals 
as well as an initiation fee 133 .  In addition to the 
meals, the program consists of one weekly session 
with a trained consultant.  The consultant is 
responsible for advising participants regarding their 
choice of prepared foods.  The choice of foods 
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includes 70 different selections.  The consultant is 
also available for telephone advice 136 . 
  
In the one published study, 517 clients attending 
Jenny Craig were surveyed by mail approximately 1 
year post treatment regarding their current weight 
status.  Of the 267 participants who responded to the 
mailed survey, it was found that 82% remained 
within 10% of their post treatment weights at the time 
of the follow-up.  Researchers concluded that the 
high relapse rates typical for this mode of treatment 
may be an artifact of premature treatment cessation 
and further investigation is  merited 137.   
Indeed, although commercial weight loss programs 
provide weight loss services with benefits of 
experience, planned menus, and psychological 
support; limitations are costs related to initiation fees 
and additional purchases such as vitamins.   
 
Atkins.  The Atkins low-carbohydrate diet has 
reigned as the high protein diet of choice for the last 
30 years.  The diet includes a elimination of 
carbohydrates of less than 20 grams per day and does 
not limit the intake of fat and animal protein.  The 
diet was a radical departure from accepted nutritional 
principles of the time 136 .  Dr Atkins responded to 
critics that the diet was deliberately unbalanced to 
counteract the metabolic imbalance that caused 
people to get fat 138 .  
  
In 2002 E. Westman 139  of Duke University, in a 
study funded by Dr Atkins's Research Foundation, 
published a 6-month study of 51 people placed on the 
Atkins diet (<25 g/d), with no limit on caloric intake 
136 . They also received nutritional supplementation 
and recommendations about exercise, and attended 
group meetings at a research clinic.  The outcomes 
were body weight, BMI, percentage of body fat 
(estimated by skinfold thickness), serum chemistry 
and lipid values, 24-hour urine measurements, and 
subjective adverse effects.  Forty-one (80%) of the 51 
subjects attended visits through 6 months.  In these 
subjects, the mean (± SD) body weight decreased 
10.3% ± 5.9% (P <0.001) from baseline to 6 months 
(body weight reduction of 9.0 ± 5.3 kg and BMI 
reduction of 3.2 ± 1.9 kg/m (2)).  The mean 
percentage of body weight that was fat decreased 
2.9% ± 3.2% from baseline to 6 months (P <0.001).  
The mean serum bicarbonate level decreased 2 ± 2.4 
mmol/L (P <0.001) and blood urea nitrogen level 
increased 2 ± 4 mg/dL (p <0.001).  Serum total 
cholesterol level decreased 11 ± 26 mg/dL (p = 
0.006), low-density lipoprotein cholesterol level 
decreased 10 ± 25 mg/dL (p = 0.01), triglyceride 
level decreased 56 ± 45 mg/dL (p <0.001), high-
density lipoprotein (HDL) cholesterol level increased 
10 ± 8 mg/dL (p <0.001), and the cholesterol/HDL 
cholesterol ratio decreased 0.9 ± 0.6 units (p <0.001).  
There were no serious adverse effects, but the 
possibility of adverse effects in the 10 subjects who 
did not adhere to the program cannot be eliminated.  
A control group was not included but the researchers 
concluded that a very low carbohydrate diet program 
led to sustained weight loss during a 6-month period 
139 . Researchers have studied the effects of isocaloric, 
energy-restricted very low-carbohydrate ketogenic 
(VLCK) and low-fat (LF) diets (-500 kcal/day) on 
weight loss, body composition, trunk fat mass, and 
REE in overweight/obese men and women in a 
randomized, balanced, two diet period clinical 
intervention study.  The goal of the VLCK diet was 
to decrease carbohydrate levels below 10% of energy 
intake and induce ketosis.  The LF diet has similar 
goals to national recommendations 
(60%carbohydrate: 25% fat: 15%).  Participants 
included 15 healthy, overweight/obese men (mean ± 
s.e.m.: age 33.2 ± 2.9 y, body mass 109.1 ± 4.6 kg, 
BMI 34.1 ± 1.1 kg/m2) and 13 premenopausal women 
(age 34.0 ± 2.4 y, body mass 76.3 ± 3.6 kg, BMI 29.6 
± 1.1 kg/m2).  Measurements of weight loss, body 
composition, trunk fat (by dual-energy X-ray 
absorptiometry), and resting energy expenditure 
(REE) were determined at baseline and after each 
diet intervention.  Results indicated that the nutrient 
intakes from food records during the VLCK (9% 
carbohydrate: 63% fat: 28% protein) and the LF 
(~58:22:20%) were significantly different.  Dietary 
energy was 1855 kcal/day in the VLCK group 
compared to 1562 kcal/day in the LF group.  The 
VLCK diet was advantageous over a LF diet for 
weight loss, total fat loss, and trunk fat loss.  
Absolute REE (kcal/day) was decreased with both 
diets but REE expressed relative to body mass 
(kcal/kg) was better maintained on the VLCK diet for 
men only.  Individual responses show that the 
majority of men and women experience greater 
weight and fat loss on a VLCK than a LF diet.  
Researchers concluded that the preferential loss of fat 
in the trunk region with a VLCK diet is novel and 
potentially clinically significant but requires further 
validation 140 .  
 
In addidtion, high protein diets have been studied in 
adolescents.  Researchers evaluated the efficacy and 
metabolic impact of a high-protein, low-
carbohydrate, low-fat ketogenic diet (K diet) in the 
treatment of six morbidly obese adolescents (aged 
12-15) with initial weights of >200% of ideal body 
weight.  The average weight was 147.8 kg (range, 
120.6-198.6 kg) with average BMI of 50.9 kg/m2 
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(39.8-63.0 kg/m2).  The intervention of the K diet was 
eight weeks.  Daily intake consisted of 650 to 
725 calories, with substantial protein (80-100 g).  The 
diet was very low in carbohydrates (25 g) and fat 
(25 g).  This was followed by 12 weeks of the K diet 
plus two carbohydrates (30 g) per meal (K+2 diet).  
Anthropometric data, blood, and urine were collected 
at enrollment, during week 1, and at 4-week intervals 
throughout the course of the study.  REE was 
measured by indirect calorimetry.  Body composition 
was estimated using dual-energy x-ray 
absorptiometry, bioelectrical impedance analysis, and 
urinary creatinine excretion at enrollment and on 
completion of each phase of the diet.  Nocturnal 
polysomnography and multiple sleep latency testing 
were conducted at baseline and repeated after an 
average weight loss of 18.7 kg to determine sleep 
architecture, frequency and duration of apneas, and 
daytime sleepiness.  Results indicated that 
participants lost 15.4 ± 1.4 kg during the K diet and 
an additional 2.3 ± 2.9 kg during the K+2 diet.  BMI 
decreased 5.6 ± 0.6 kg/m2 during the K diet and an 
additional 1.1 ± 1.1 kg/m2 during the K+2 diet.  Body 
composition studies indicated that weight was lost 
equally from all areas of the body and was 
predominantly fat and lean body mass was not 
significantly affected.  Weight loss was accompanied 
by a reduction in REEnof 5.2 ± 1.8 kcal/kg of fat-free 
mass per day.  Blood chemistries remained normal 
throughout the study and included a decrease in 
serum cholesterol from 162 ± 12 to 121 ± 8 mg/dL in 
the initial 4 weeks of the K diet.  A paucity of rapid 
eye movement sleep and excessive slow-wave sleep 
were seen in all subjects at enrollment.  Weight loss 
led to an increase in rapid eye movement sleep 
(P < .02) and a decrease in slow-wave sleep (P < .01) 
to near normal levels.  Researchers concluded that the 
K diet could be used effectively for rapid weight loss 
in adolescents with morbid obesity without loss of 
lean body mass, with normal blood chemistries and 
sleep abnormalities that significantly decrease with 
weight loss.  Although there are some clinical 
investigations showing promise with high protein 
diets, there are some concerns associated with high 
protein diets 141 .  
 
Protein Diet Limitations.  Fiber intake in high 
protein diets falls short in the daily-recommended 
allowance requirements.  Dietary fiber is linked to 
total food intake and calorie intake.  The current fiber 
recommendation for men is 38g/day and women, 25 
g/d.  The recommendations differ due to unique 
caloric requirements for the individual genders.  
Americans typically consume 10-13 g of fiber per 
1000 kcal consumed 142 .  The fiber level of popular 
protein diets ranged from 4 g to 10.6 of dietary fiber.  
Two of the most popular high protein diets, Atkins 
and the South Beach diet are designed with different 
phases of kcal/d and include dietary fiber.  However, 
both plans do not supply recommended intakes of 
fiber.   Despite their efforts to include fruits, 
vegetables, and whole grains, the dietary fiber ranges 
were ranging from extremely low levels of only 1.6 
g/d to less than 10 g/d at the maximum 
recommendations 142 .  Dietary fiber is an integral part 
of basic nutrition due to its protective effects against 
industrialized diseases such as diabetes, cancer, heart 
disease, and obesity.  Researchers have also noted a 
link to weight management and fiber intake.  In the 
Nurses’ Health Study, weight gain was inversely 
associated with intake of high fiber, (i.e., whole grain 
foods) but positively associated with intake of refined 
grain foods 142 .  There is also evidence to suggest 
fiber contributes to satiation.  Clinical studies have 
found that low glycemic breakfasts, which were 
higher in dietary fiber, decreased food intake in 
preadolescent children 143 .    
 
Medical specialists in the field of preventive 
cardiology feel that low carbohydrate, high-protein 
diets have shown promising results in the area of 
lipid profiles and weight loss.   However, safety and 
efficacy beyond 24 weeks has yet to be determined 
144 .  Considerations for patients on low-carbohydrate-
-high-protein diets (LC-HP) should include the 
following information.  The long-term (greater than 6 
months) consequences of an LC-HP, hypocaloric diet 
are unknown, these diets do not meet the nutritional 
requirements for many vitamins, minerals and dietary 
fiber, and should not be used in a long term health 
plan for weight management in patients who smoke, 
have cardiovascular disease, diabetes, hypertension, 
or hyperlipidemia..  It has yet to be determined how 
safe LC-HP diets are in special populations 144 .   
 
Low Glycemic Diets.  Sugar Busters is a type of 
low carbohydrate, low glycemic, high protein diet 145.  
The diet focuses on reducing high-glycemic 
carbohydrates to lower insulin levels and decrease 
insulin-resistance.  The concept is to consume foods 
with a low-glycemic index, and fats in moderation.  
The Sugar Busters diet is lower in fat and protein 
than the Atkins, consisting of 32% of its energy from 
fat, 28% from protein and 40% from carbohydrate.  
The diet allows lean meats, eggs, non-starchy 
vegetables, fruits, dairy products, whole grains and 
nuts.  It provides 280 mg/day of cholesterol and 24 
grams/day of fiber 146 .  A study that looked at obese 
females in a 12-week parallel arm study followed by 
a 12-week crossover study found that the low-GI 
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energy-restricted diet produced greater weight loss 
and a greater reduction in fasting insulin levels in 
both studies than did the isocaloric, macronutrient 
balanced, high-GI diet 147 . In another study 
comparing a low GI diet against a high GI diet of 
equal energy and macronutrient content in 
overweight men for 5 weeks, researchers showed that 
there was a reduction in total fat mass by 500 g, as 
measured by dual x-ray absorptiometry 148 .   Another 
study compared the effects of a reduced glycemic 
load diet with those of an energy-restricted, reduced-
fat diet in obese adolescents over a 6-month 
intervention and a 6-month follow-up.  At 12 months, 
the authors found that both BMI (-1.3 ± .7 vs .7 ± 0.5; 
p = .02) and fat mass (-3.0  ±1.6 vs 1.8 ± 1.0 kg; p = 
.01) were significantly lower in the reduced-GL 
group compared with the reduced fat group 149 .  In a 
retrospective, nonrandomized study of the effects of a 
low-GI diet (n = 64) compared with a conventional 
reduced-fat diet (n = 43) in the management of 
pediatric obesity, greater decreases in BMI and body 
weight were seen in the low-GI group, even after 
adjustment for age, sex, ethnicity, baseline BMI, and 
baseline weight 150 . 
 
Physician Supervised Diets.  Many patients who 
are dealing with being overweight or obese 
accomplish weight loss with diet, exercise and 
lifestyle changes.  Some patients may require 
physician supervised dietary management.  The 
greatest loss in body weight, especially of body fat 
within a definite period of time is achieved by diets 
that provide only 400-800 kcals per day.  Successful 
very low calorie diets (VLCDs) were associated with 
significantly greater maintenance of weight loss than 
were low calorie diets at follow up points.  In a meta-
analysis of 29 studies looking at long-term 
maintenance of weight loss in individuals completing 
structured weight loss programs, the initial weight 
loss was 17 kg with VLCDs vs. 6.5 kg with the low 
calorie diet.  After 5 years it was 7 kg vs. 2 kg 
respectively 151 .   Low fat diet plans can also be an 
option.  Several meta-analyses show that a reduction 
in dietary fat without restriction of energy intake 
produces a modest but clinically meaningful 2.5 kg 
weight loss in overweight subjects 152 .  Thirty-six 
diabetic subjects were randomly assigned to a 
standard behavior therapy program or to a behavior 
therapy program that included an 8-week period of 
VLCD.  In this study, thirty-three of the 36 subjects 
completed the 20-week program and the 1-year 
follow-up.  Use of the VLCD produced greater 
decreases in fasting glucose at the end of the 20-week 
program and at 1-year follow-up.  The VLCD group 
also had greater weight losses at week 20, but weight 
losses from pretreatment to 1-year follow-up were 
similar in the two treatment groups 153 .  In another 
study, researchers evaluated the use of a ketogenic, 
very-low-calorie diet (VLCD) in the treatment of 
type 2 diabetes in 20 children (mean age 14.5 ± 0.4 
years).  Mean daily blood glucose values fell from 
8.9 ± 1.1 to 5.5 ± 0.38 mmol/l (P < 0.0001) in the 
first 3 days of the VLCD.  BMI fell from 43.5 ± 1.8 
to 39.3 ± 1.8 kg/m2 (P < 0.0001) and HbA1c dropped 
from 8.8 ± 0.6 to 7.4 ± 0.6% (P < 0.005) as the diet 
was continued for a mean of 60 ± 8 days (range 4–
130 days), and none required resumption of anti-
diabetic medications.  Sustained decreases in BMI 
and insulin requirements were observed in patients 
remaining on the VLCD for at least 6 weeks when 
compared with those of the control group 154 . 
 
Physical Activity 
 
Modification focused on increasing physical activity 
should include reinforcement of physical activity and 
limitation of sedentary time. The theory of planned 
behavior has been applied extensively in the study of 
exercise. Behavioral intentions are determined by 
three independent constructs: perceived behavioral 
control, subjective norm (perceived social pressure to 
perform the behavior), and attitude (positive-negative 
evaluations of behavior).  Thus, people are more 
likely to participate in physical activity if they have a 
positive attitude towards it, if they perceive social 
pressure, and if they believe they will be successful 
155 .  Accordingly, for exercise programs to be 
successful for both adults and children, these 
dimensions need to be reinforced.    
 
Children and Adolescents 
 
Behavioral approaches, pharmacologic approaches, 
and surgical approaches are available for the 
treatment of overweight and obesity in children and 
adolescents.  In addition to exercise, several dietary 
approaches are available. With children and 
adolescents, sedentary time should be limited to no 
more than two hours per day and physical activities 
should be enjoyable to reinforce participation 127 .  
Using four randomized treatment studies, Epstein et 
al. 156 , found ongoing longitudinal success after a 
childhood behavioral weight management 
intervention.  After 10 years, 30% were not obese and 
34% decreased percentage overweight by 20% or 
more.  Significant effects indicate long-term changes 
in children depend on the treatment with emphasis on 
the family and other sources of support for eating and 
activity change.  Terence 157  indicates that the effect 
of behavioral therapy for weight loss in childhood 
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may be longer lasting than that seen in adults because 
it may be easier to teach children healthy eating and 
activity habits.  Also, the importance of self-control 
is reduced since parents regulate access to food 157 .  
In addition, cognitive-behavioral treatments seem to 
be more effective in children when delivered before 
puberty than they are for adults 131 . 
  
Efforts to reduce fast-food consumption may be a 
useful strategy in improving diet.  The National 
Heart, Lung, and Blood Institute Growth and Health 
Study is a 9-year, longitudinal biracial cohort study 
with annual 3-day food records.  This observational 
study included 2379 girls (1,166 Caucasian and 1,213 
African American), aged 9 or 10 years at baseline.  
Trends in fast-food consumption and the relationship 
to calorie, fat, and sodium intake were examined.  
Data collection occurred annually using a validated 
3-day food record and a food-patterns questionnaire, 
which compare patterns of exposure to fast food and 
its impact on intake of calories, fat, and sodium.  
Results indicated that fast-food intake was positively 
associated with intake of energy and sodium as well 
as total fat and saturated fat as a percentage of 
calories.  In addition, as both groups aged, fast-food 
intake increased in both races.  The mean energy 
intake in the low fast-food frequency group was 1837 
kcal.  Sodium intake was 3085 mg, total fat was 
34.3%, and saturated fat was 12.5%.  In contrast, the 
adjusted mean was 1966 kcal for the highest fast-
food frequency group, sodium intake was 3236 mg, 
total fat was 35.8% and saturated fat was 13%.  
Researchers concluded that dietary intake of fast food 
is a determinant of diet quality in both black and 
caucasion adolescent girls 158 .  
  
Data from the same study measured the frequency of 
breakfast consumption, dietary calcium and fiber, and 
BMI by age and race.  Generalized estimation 
equations analyses were also conducted to test 
whether breakfast consumption was predictive of 
intake of dietary calcium and fiber, as well as BMI.  
Results indicated that the frequency of breakfast 
eating declined with age and caucasion girls reported 
more frequent breakfast consumption than African-
American girls.  However, racial difference decreased 
with increasing age.  Higher calcium and fiber intake 
in all models were associated with days eating 
breakfast regardless of adjustment variables.  In 
addition, days eating breakfast were predictive of 
lower BMI in models that adjusted for basic 
demographics (i.e., site, age, and race), but the 
independent effect of breakfast was no longer 
significant after parental education, energy intake, 
and physical activity were added to the model.  
Researchers concluded that Dietetics professionals 
need to promote the importance of consuming 
breakfast to all children and adolescents, especially 
African-American girls 159 . 
 
Multifactoral Approaches 
 
An important development in behavioral treatment of 
obesity has been the attempt to identify subgroups 
that might benefit from specific management 
approaches160 . Behavioral weight management 
programs for participants identified with binge eating 
disorder is challenging due to the difficulty in 
collecting dietary information.  Personnel who work 
with this population may require additional training 
in identifying and understanding the psychological 
characteristics of participants with binge-eating 
disorder, 161  with treatment influenced by techniques 
developed for other types of eating disorders such as 
bulimia 162 .  Also, behavioral modification is 
essential in managing postmenopausal obesity and 
overweight since regular physical activity is a crucial 
component of the modification for the reduction of 
obesity-related morbidity and mortality in the 
postmenopausal years 163 .  In addition, the treatment 
regimen for metabolic syndrome should first include 
lifestyle modifications including behavioral change to 
reduce caloric intake and the increase of physical 
activity, in addition to the focus on individual 
components 164 . Behavioral strategies used in 
conjunction with medical treatment can be applied to 
adults, adolescents, and children.  In a 54-week 
randomized, double-blind study of 539 obese 
adolescents, researchers concluded that when orlistat 
was  combined with diet, exercise, and behavioral 
modification, there was statistically significant 
improvement in weight management in obese 
adolescents compared with placebo 165 .  
 
In spite of recommendations to include behavioral 
modification, researchers found that lifestyle 
treatments, with the exception of dietary components, 
have not been widely used in randomized, placebo-
controlled obesity-drug trials.  In the 1990s, less than 
one-half of studies reported using behavioral 
strategies.  A balanced-deficit diet used 41.4% of the 
time was the most used dietary component, low-
calorie diets were second (24.5%), and self-
monitoring was third overall.  Self-monitoring was 
the most used behavioral modification component 
and none of the other specific lifestyle treatments 
were implemented in more than 5% of obesity drug 
trials.  In addition, lifestyle exercise and walking 
were rarely incorporated into drug studies, even in 
the 1990s.  These data suggest that the design of 
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obesity drug trials do not provide comprehensive 
treatments 132 .  The first strategy in the treatment of 
overweight and obesity should include behavior 
modification.  However, if not successful, other 
methods such as medications and surgery may be 
necessary. 
 
Supplements and Weight Loss 
 
There are several supplements available on the 
market to assist overweight and obese individuals 
with weight loss.  Among the most popular and 
effective weight loss supplements are ephedra and 
caffeine.  Despite a recent ban of ephedra by the 
Food and Drug Administration, studies have shown 
that together, caffeine and ephedra promote about 
two pounds of extra weight loss per month while 
dieting 166-169 .  Greenway et al. 168  found that a 
combination of ephedra and caffeine supplementation 
was a more cost-effective treatment for reducing 
weight, cardiac risk, and LDL cholesterol than 
several weight loss drugs 170 .  Additionally, Boozer 
and associates 166  reported that six months of herbal 
ephedra and caffeine supplementation promoted 
weight loss with no clinically significant adverse 
effects in healthy overweight adults 170 .   
  
Among the less popular supplements that have 
clinically shown to have an effect on weight loss are 
calcium and green tea extract.  Calcium has been 
shown to suppress fat metabolism and weight gain 
during periods of high calorie intake , and to increase 
fat metabolism during caloric restriction 171 .  Green 
tea extract has been theorized to increase energy 
expenditure by stimulating brown adipose tissue 
thermogenesis 170 .  Studies show that, with caffeine, 
green tea increased 24-hour energy expenditure and 
utilization of fat in humans 172 . 
  
In addition to the previously discussed supplements, 
there are several other types of supplements available 
on the market, but there is little or no research 
showing the effects on weight loss.  For example,  
Gymnema Sylvestre has been shown to affect fat 
metabolism, blood lipid levels, and fat deposition in 
rats 173 , but there are no published studies that have 
observed these same effects in humans170 .   Garcincia 
cambogia (HCA) has been shown to increase fat 
metabolism in animal studies 174 , but there is little or 
no evidence showing the effect of HCA 
supplementation on body composition in humans 175 .  
Similarly, Conjugated linoleic acids (CLA) have also 
been reported to decrease fat deposition in animals 
176, 177 , but more recent studies indicate that CLA 
supplementation in humans has no effect on body 
composition alterations in either trained or untrained 
individuals 178, 179 .  Chromium was originally 
believed to improve fat loss during resistance training 
180, 181 , but with the use of more accurate methods of 
assessing body composition, studies have reported no 
effects on body composition in healthy individuals 
182, 183 .  Despite the lacking evidence in support of 
these supplements, many are available to the public 
and are marketed promoting their ability to help with 
weight loss.  
 
Medical Management 
 
It may be more appropriate for some who are 
overweight or obese to use weight loss medications.  
Medications used for the treatment of obesity are 
formulated to reduce energy intake, increase energy 
output or decrease the absorption of nutrients.  Diet, 
exercise and lifestyle changes are all still the 
foundation to weight loss and cannot be replaced 
with drugs.  There are three types of medications 
used for the treatment of obesity and all are based on 
their mechanism of actions.  There are medications 
that suppress appetite, alter nutrient absorption and 
increase energy expenditure 152 .  There are two 
medications currently approved by the FDA for long-
term use in the management of obesity; sibutramine 
and orlistat 184 . 
 
Pharmacological.  Medications should only be 
considered for patients with a BMI greater than 30 or 
greater than 27 if they have co-morbidities and have 
failed to lose weight on a program of diet, exercise, 
and behavior therapy 185 .  Sibutramine is a novel 
agent that inhibits the reuptake of serotonin, 
norepinephrine, and dopamine 151 .   It does not 
stimulate secretion of serotonin.  Its affects on food 
intake are caused by increased noradregenic and 
serotonergic activity in the central nervous system 186 
.  Sibutramine has been shown to reduce energy 
intake, specifically during lunch time 184 .  In a one 
year study, researchers examined the effect of 
sibutramine on weight loss.  Patients in this study 
took a daily dose of 10 mg of sibutramine.  The 
results showed that the patients on sibutramine had a 
mean weight loss of 4.8 kg, whereas the patients on a 
placebo lost a mean of 1.8 kg.  Orlistat is an agent 
that inhibits gastrointestinal lipase.  The resulting 
lower gut enzyme activity reduces by approximately 
one third the amount of fat that is absorbed from 
food.  It is a reversible inhibitor and it binds 
covalently in the lumen with the active serine residue 
of gastric and pancreatic lipases.  Depending on the 
fat content of a person’s diet, this lowered absorption 
can represent 150 to 200 kcal/day 187 .   Orlistat does 
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not affect the central nervous system and does not 
have a direct affect on appetite.  It induces weight 
loss by principally blocking the absorption of about 
one third of the fat consumed in a meal 184 .  A study 
that was consistent with the idea reported that fat 
intake was generally higher in placebo group than in 
the orlistat treated group 184 .  A clinical investigation 
required participants to follow a low fat energy 
restricted diet and take 120 mg of orlistat 3 times a 
day or a placebo for one year.  The mean weight loss 
was 9% in the orlistat group vs. a mean weight loss 
of 5.8% in the placebo group 185 .     
 
Medical Management with Behavior Change.  
Medication is often recommended to individuals who 
have difficulty losing weight with diet, exercise, and 
behavior therapy.  There is growing evidence that 
shows that a program consisting of physical activity 
can reduce the risk for cardiovascular disease.  By 
introducing a behavior treatment that encourages a 
person to eat low fat, low-cholesterol foods, they 
reduce the risk of coronary artery disease.  In 
addition, if a lifestyle modification was not employed 
in combination with obesity medications, 
medications alone might result in suboptimal short 
and long-term weight losses.  Adding 
pharmacotherapy to lifestyle modification fits well 
with a stepped care approach in which the least 
aggressive intervention is tried first and then, if 
unsuccessful, is augmented by more aggressive 
interventions 184 .   
 
There have been multiple studies done to examine 
whether adding medications will improve the results 
of lifestyle modification.  In a study done with 
sibutramine, results showed a weight loss of  3 to 9 
kg greater than placebo when both interventions were 
combined with a low intensity program of lifestyle 
modification 184 .  In a study using orlistat plus 
lifestyle modification, weight losses were 2 to 6 kg 
greater than those resulting from placebo plus 
lifestyle change 184 .  In a studies of 1 to 2 years in 
durations, sibutramine produced an average weight 
loss of 7 to 10 kg, which was 5 kg greater than 
placebo plus lifestyle change.  In a two year study 
orlistat produced weight loss averaging 5 to 8 kg, 
which was 4 kg greater than the placebo.  
 
Other Medical Options.  Bariatric surgery can be 
an option for some obese individuals if the patient 
has a BMI ≥ 40 kg/m², BMI of 35 to 40 kg/m² who 
have a high risk of co-morbid conditions or have 
significantly obese related physical conditions that 
interfere with their lifestyle.  There are two 
procedures commonly performed. One is vertical 
banded gastroplasty, in which a small pouch with a 
restricted outlet is constructed along the lesser 
curvature of the stomach.  The second is gastric 
bypass, in which a proximal gastric pouch is 
constructed whose outlet is a Y-shaped limb of the 
small intestine 152 .  Life long medical surveillance is 
necessary after surgical therapy 151.   Health 
Insurance Commission data indicate a steady and 
steep increase in bariatric surgery with 399 
procedures, mainly gastric stapling of various types, 
performed in 1993 and 2,992 procedures in 2003 188 . 
Depending on the procedure and the program, the 
surgery and related care may cost $20,000 to $50,000 
189 . The major complications of bariatric surgery 
include pulmonary embolism, respiratory failure, 
gastrointestinal leaks from the breakdown of the 
staple or suture line, stomal obstruction or stenosis, 
and bleeding 189 . The risk of death following bariatric 
surgery is between 1% and 2% in most series, but is 
significantly higher in patients with respiratory 
insufficiency of obesity 190 . 
 
RESEARCH DESIGN CONSIDERATIONS IN 
THE STUDY OF OBESITY 
 
A good research design begins with a valid question 
that needs to be answered.  Over the last 25 years, 
there has been a growing need for sound research in 
the area of obesity and weight management.  With 
the incidence of “over weight” in the United States 
increasing to over 64%, the need for treatment has 
risen.  The research design begins with assessing the 
feasibility of the study objectives and considering 
alternative research designs.  The researcher must 
then define the study population and key concepts in 
operational terms.  Special care must be given in 
selecting methods of sampling, data collection, and 
analysis appropriate to the study's objectives.  
Finally, the research team must develop realistic 
budgets and time schedules for each stage of the 
research.  
 
Research Question and Experimental Design                         
 
The research design must begin with a valid question.  
The question must have a need to be answered within 
the scientific community.  The research facility must 
have the ability, such as personnel and equipment, to 
answer the question.  Furthermore, the research 
design must be one that controls for the largest 
amount of error and bias, at the same time clearly 
addressing the research question.  A meta-analysis 191  
completed in 1997 concluded that in over 700 
research studies reviewed diet plus exercise was the 
most effective treatment in weight reduction.  Classic 
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experimental methods employed to test specifically-
designed hypothesis about diet-disease relationship 
should be a randomized control trial 109 .  A 
randomized controlled trial (RCT) is an experiment 
in which investigators randomly assign eligible 
subjects into groups to receive or not receive one or 
more interventions that are being compared.  The 
results are analyzed by comparing outcomes in the 
groups.  RCT studies help control confounding 
variables associated with this type of research.  
Control subjects are included in clinical trials to 
quantify and correct for the influence of 
compounding or confounding factors that introduce 
bias to the results of a specific treatment.  Therefore 
all studies assessing the effectiveness of a treatment 
in achieving weight loss must include a control or 
comparison group, irrespective of whether they are 
examining drugs, diet, lifestyle or other treatments 
109.  Subjects in an RCT could not be randomly 
assigned to lose or not lose weight; they could only 
be randomly assigned to receive or not receive 
interventions that might result in weight loss 160 .  If 
participants in an RCT were randomly assigned to 
several interventions that produce weight loss 
through different mechanisms and these interventions 
yielded similar improvements in health status, then 
the conclusion that weight loss was responsible for 
the improvements in health outcomes may be 
justified 160 . 
 
Study Subjects                                                                                                              
 
Carefully selecting a study design and population 
facilitates the creation of new knowledge while 
avoiding important errors.  The overwhelming 
majority of subjects that have been used in weight 
loss trials have been moderately obese and middle 
aged 191 . Furthermore, the subjects’ demographics 
have had little variation.  On average subjects’ 
demographics were age (40y), body weight (96kg), 
BMI (35), and program length (15w) 191 .  A 
significant source of error is that subjects who 
volunteer for studies of weight loss want to lose 
weight so they are ready to attempt to make lifestyle 
changes.  Their recruitment with overweight as a 
selection criterion usually results in weight loss in 
addition to or even without specific treatment or 
advice.  Control groups for diet and lifestyle studies 
may be offered no advice, or usual or routine 
treatment, but this may confuse the analysis because 
such subjects recruited as volunteers for weight loss 
inevitably do make extra changes, thus lose weight to 
a variable degree. 
 
 
Sources of Error and Bias 
 
Many sources of error and bias exist when 
conducting obesity and weight management research.  
The goal of the research team is to identify and 
attempt to control for those variables.  Various 
physical, psychological, and emotional factors may 
complicate obesity treatment and/or interpretation of 
results.  As previously mentioned the participants 
themselves are the cause of some error.  Subjects 
recruited based on weight, BMI, and sedentary 
lifestyles are looking to make a lifestyle change.  
Thus, it must be expected that even the controls 
might loose weight.  According to Yanovski 160 , it 
may be feasible to maintain control groups who do 
not lose weight in long-term studies by providing 
them with a minimal intervention of a self-help 
manual on weight loss and healthy eating. Obese 
control groups often have greater retention rates than 
do treatment groups.  This result is believed to be 
attributable to the control group members feeling less 
embarrassed than their intervention group 
counterparts if they do not lose weight or if they 
regain lost weight 160 .   
 
One of the primary issues in obesity research is that 
of diet records.  Over the last several years, the 
importance of evaluation of nutritional intervention 
with exercise has come to be a top priority.  
However, one of the largest sources of error is that of 
dietary recall.  In a perfect world, researchers could 
monitor all food intake for there study participants.  
This is logistically impossible, unless your 
participants are in house.  Thus, all conventional 
methods of dietary adherence depend on subjects' 
reports.  Most labs lack independent biochemical, 
physiological or genetic measures of dietary intake.  
Therefore, we do not know if subjects actually follow 
the diets being tested and compared.  We also know 
that most subjects in “weight loss” studies under-
report their energy intake and its components 192 . The 
sad reality is that we do not actually know if the 
results of any current diet trials are valid or reliable.  
Winkler 193  has identified three ways in which 
researchers can help control diet intervention studies: 
(1) biomarkers of intake for energy, macro- and 
micro-nutrients and other food components relevant 
to weight gain/loss; (2) field measuring instruments 
that are cheap, rapid, painless, non-intrusive and self-
administrable; and (3) electronic data transmission 
systems that preclude subjects' ability to misreport.   
  
Other sources of error include few entry criteria for 
participants, pre-menstrual fluid accumulation 
(gender), recruiting participants who have already 
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participated in weight-loss studies, insufficient 
statistical power, too short study duration, poor 
matching for age, or unusual age distribution, just to 
name a few 109 .  No study will be able to control for 
all of these sources of error, thus care should be taken 
to limit the impact of these sources of error/bias 
and/or account for them in statistical analysis.  One 
of the areas that the researchers can control is that of 
collection and recording of data.  Researchers should 
use the most valid and reliable forms of measurement 
available to them such as DEXA for body 
composition and bone density 194 , Calibrated digital 
scale, and BIA for body water 195 .  Researchers can 
also limit error by providing metabolic data, such as 
that of REEor VO2 measurements while exercising.   
 
Future Directions 
 
In 2004, the Department of Health and Human 
Services (DHHS) in collaboration with National 
Institutes of Health (NIH) created a program 
announcement to outline the type of obesity/weight 
loss research that is needed 196 .  As previously 
mentioned and outlined through meta-analysis 191 , 
weight loss research has been narrowly focused on 
the population and time frame.  With this mind, the 
DHHS and NIH have outlined ten areas that should 
be the focus of future research as follows:  
   
1) Studies that investigate biological 
mechanisms underlying weight regain after 
intentional weight loss (neuroendocrine, 
endocrine, and gastrointestinal function, 
muscle and adipocyte biology, etc);  
2) Investigations of appetite and food 
intake during weight maintenance and 
regain periods (including energy intake, 
macronutrient preference, micronutrient 
intake from foods and supplements, 
eating behaviors, binge-eating); 
3) Studies to elucidate the role of energy 
expenditure during weight regain after 
intentional weight loss (including 
voluntary physical activity, thermic 
effect of feeding, nonexercise-activity 
thermogenesis, 
sympathetic/parasympathetic nervous 
system function); 
4) Studies of the effects of age-related 
changes on responses to weight 
maintenance interventions, including 
effects on body composition, metabolic 
regulation and other physiologic 
responses; 
5) Clinical studies that evaluate the impact 
of behavioral interventions such as 
extended or more frequent patient 
contact, use of technology  to enhance 
self-monitoring behaviors, social 
supports, motivational interviewing, etc. 
on improved weight maintenance;  
6) Studies of dietary strategies to enhance 
long-term weight maintenance (such as 
meal replacements, alterations in nutrient 
density or macronutrient composition); 
7) Studies using approved or 
investigational weight loss agents to 
enhance weight maintenance or prevent 
regain after weight loss;  
8) Clinical studies evaluating the impact of 
differing types, intensity, and frequency 
of physical activity on long-term weight 
maintenance;  
9) Innovative interventions that incorporate 
the sociodemographic and cultural 
factors thought to influence weight 
maintenance;  
10) Innovative methods to promote long-
term weight maintenance in persons with 
mobility-limiting conditions.  
 
Athletes and Weight Loss 
  
As stated above, weight loss is achieved by a 
decrease in energy intake and an increase in energy 
expenditure.  In the case of an athlete, it is assumed 
that energy expenditure is adequate.  Therefore, the 
focus of an athlete wanting to lose fat mass should be 
on energy intake.  Prior to reducing caloric intake, it 
is imperative that a preliminary body composition 
assessment be completed 197 .  This is necessary so 
that changes in fat mass and fat free mass can be 
documented throughout the reduction in energy 
intake.  It is important (especially for the athlete) that 
the bodyweight lost is a result of a reduction of fat 
mass and not skeletal muscle.  After an initial body 
composition assessment, periodic assessments should 
follow.  When efforts to induce these body changes 
are approached with sound principles of nutrition and 
training, the resulting changes in body composition 
can make the desired contribution to health and 
fitness as well as contributing to increasing the 
athlete's performance potential 198 . 
  
Body weight goals of athletes should be 
individualized and based on the requirements of the 
sport, the athlete's body size and shape, and in 
consultation with the athlete, coaches, and trainers.  
Safe weight loss goals should be established on an 
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individual basis 199 .  Athletes, coaches, and trainers 
should work closely with individuals who have 
training in nutrition (registered dietitians and sports 
nutritionists) to set appropriate weight goals and to 
develop weight management protocols that promote 
healthy eating 199 .  Athletes who use drastic food or 
fluid restriction to lose weight may experience 
negative consequences, including loss of lean tissue, 
hormonal disturbances, and performance impairment 
200 .  While there are no standard guidelines set for 
athletes in terms of the amounts of caloric restriction, 
some recommendations have been given: decreasing 
energy intake by 500 kcal/day or 300 to 520 kcal/day 
201 ; consuming 38 kal/kg (17 kcal/lb) for men and 35 
cal/kg (16 kcal/lb) for women202 .  
 
In summary, weight loss is not commonly the goal of 
athletes.  However, when weight loss is desired, it is 
important that the resultant decreases in body weight 
be directed towards fat mass.  Following the 
aforementioned strategies may assist the athlete in 
accomplishing their weight loss goals.     
 
CONCLUSION 
 
The prevalence of morbidly obese Americans is 
estimated to have increased three-fold from 1990 to 
2000.  Obesity is not only a problem in the United 
States but is also a major health concern in Europe 
and other regions of the world.    The associated 
effect of obesity on type 2 diabetes, hypertension, 
coronary heart disease (CHD), gallbladder disease, 
osteoarthritis, and certain cancers gives rise to the 
increasing economic costs of obesity.  The total 
annual medical expenditure cost for the United States 
has been estimated to be 5-7% of total health care 
costs or about 75 billion dollars a year.  Thus, the 
need for preventative techniques, as well as, 
treatment has never been greater.  Historically, 
obesity has been thought to simply be related to an 
imbalance between energy intake and expenditure.  
However, more recent research has suggested that 
genetic, physiological, and behavioral factors also 
play a significant role in the etiology of obesity.    
There are many ways to treat and prevent obesity.  
Today’s market is flooded with weight loss drugs, 
surgeries, and fad diets.  However, eating a proper 
diet and maintaining a relatively active lifestyle is the 
most effective means to prevent and treat obesity.  
Although it seems simple enough, there is still a need 
for research in this area.  There needs to be further 
research on the genetic and hormonal aspects of 
obesity such as CCK, grehlin, leptin, and cortisol.  
There is also a strong need for long-term weight 
maintenance studies.  Commonly research focuses on 
short-term weight loss, but not maintaining the 
weight loss.  Finally, there is a need to study the 
effects of obesity in sports.  In recent weeks, some 
questions have been raised about the health of 
professional athletes who carry 300+ pounds.  While 
most are athletically talented, they are still clinically 
obese.  Thus, there is a growing need to evaluate the 
physical stress associated with obesity in athletes.   
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